317 related articles for article (PubMed ID: 15876400)
1. Targeting of therapeutic agents to bone to treat metastatic cancer.
Bagi CM
Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
4. How can we improve the treatment of bone metastases further?
Coleman RE
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S7-13. PubMed ID: 9801853
[TBL] [Abstract][Full Text] [Related]
5. Bone continuum of cancer.
Lipton A
Am J Clin Oncol; 2010 Jun; 33(3 Suppl):S1-7. PubMed ID: 20526089
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
Freedman OC; Amir E; Clemons MJ
Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
[TBL] [Abstract][Full Text] [Related]
7. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
Horváth Z
Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
Lipton A
J Support Oncol; 2004; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
[TBL] [Abstract][Full Text] [Related]
10. Metastatic bone disease: future directions.
Clohisy DR
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S95-9. PubMed ID: 14600597
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer bone metastasis and current small therapeutics.
Cicek M; Oursler MJ
Cancer Metastasis Rev; 2006 Dec; 25(4):635-44. PubMed ID: 17160709
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
14. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
[TBL] [Abstract][Full Text] [Related]
15. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
16. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
18. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Powles T; McCroskey E; Paterson A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
[TBL] [Abstract][Full Text] [Related]
19. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
20. Bone-directed treatments for prostate cancer.
Saad F
Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
